Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
Oncimmune is not the only company looking to use the immune system to diagnose cancer. But its growth plans are intense, and it intends to prove the economic benefits of…
In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Guardant Health says its tests have a market opportunity of $35bn, and now has to justify investors’ faith.
The first quarter of this year saw more venture funding raised by medical device groups than any other period since 2010.
The first data emerge from the circulating cancer genome atlas trial.